leisure time -WSS

leisure time

author：leisure time 2025-10-02 16:00:51 - browse：2743

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： How to bring more disabled researchers into academia

WSS

CDC concerned about possible undetected monkeypox spread in U.K.

Why we need to separate burnout from moral injury in health care

Why are elite athletes different? Take a look at their microbes

Donald Trump's relentless attacks on special counsel Jack Smith

The problem with charging patients to message their doctors

RSV shot was 90% effective at preventing hospitalizations in kids

hotspot

leisure time

leisure time

Affirmative action in medical school literally saved lives

Air quality improving but still lags in Black, Hispanic communities

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Sen. Paul opposes bill to ban Chinese biotechs

What does generative AI mean for health care? We asked experts

Gene therapy has helped boys walk. Can scientists keep it that way?

At least 13 dead in Texas as scorching temps continue

In his State of the Union, Biden takes clear aim at 'Big Pharma'

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CDC marks new Covid

entertainment

Colonoscopy at 40? Study finds a possible benefit

RSV shot was 90% effective at preventing hospitalizations in kids

Why drug prescriptions should include diagnoses

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

The strategy behind pharma's lawsuits over drug pricing reform

Air quality improving but still lags in Black, Hispanic communities

hotspot

Wikipedia

hotspot

knowledge